Sales & Marketing

Continued approval to be based on verification and description of clinical benefit in confirmatory trials.

Joint venture to combine artificial intelligence with biosciences’ dataset to identify novel therapy targets.

Collaboration intends to inspire creativity in healthcare and pharma industries.

New indication focuses on metastatic rearranged during transfection fusion-positive non-small cell lung cancer.

Partnership aims to identify small molecule candidates’ activity towards tumor suppressor protein.

Treatment indicated for patients aged 12 months and older.

The precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.

Clinical trials report Izervay slowed disease progression as early as six months.

Extension complements pharmaceutical’s total lab solutions portfolio.

Decision comes amid recommendation from agency’s Committee for Medicinal Products for Human Use.

Treatment indicated for adult patients with metastatic colorectal cancer.

Deal comes amid companies’ bankruptcy filings.

Addition expected to provide approximately $1 billion in capital.

Agreement includes request to dismiss pending lawsuit.

Treatment is the first of its kind to focus on endometrial cancer.

Industry veteran Charles Pirraglia demystifies the journey of bringing life-changing therapies to the Canadian market, from understanding drug pricing to navigating direct-to-consumer advertising rules.

New deal to focus on commercialization efforts in Latin America.

Total deal expected to be worth approximately $7.3 billion.

Partnership intended to enhance development plan of biopharma’s drug candidate.

Research discovered no new safety signals.

Balfaxar indicated for restoration of blood coagulation.

Medicine indicated for adults and pediatric patients aged two and older.

Medicine developed in collaboration between Boehringer Ingelheim and Eli Lilly.

Treatment is the first approved for eyelid disease.

Collaboration aims to treat hypertension in patients with high cardiovascular risk.